Melanocyte-Stimulating Hormone Receptor (Melanocortin Receptor 1 or MC1-R or MC1R or MSHR) - Pipeline Review, H1 2016

  • ID: 3746929
  • Report
  • Region: Global
  • 60 pages
  • Global Markets Direct
1 of 6

FEATURED COMPANIES

  • Mallinckrodt Plc
  • Retrophin Inc.
  • MORE
Melanocyte-Stimulating Hormone Receptor (Melanocortin Receptor 1 or MC1-R or MC1R or MSHR) - Pipeline Review, H1 2016

Summary

‘Melanocyte-Stimulating Hormone Receptor (Melanocortin Receptor 1 or MC1-R or MC1R or MSHR) - Pipeline Review, H1 2016’, provides in depth analysis on Melanocyte-Stimulating Hormone Receptor (Melanocortin Receptor 1 or MC1-R or MC1R or MSHR) targeted pipeline therapeutics.

The report provides comprehensive information on the Melanocyte-Stimulating Hormone Receptor (Melanocortin Receptor 1 or MC1-R or MC1R or MSHR), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Melanocyte-Stimulating Hormone Receptor (Melanocortin Receptor 1 or MC1-R or MC1R or MSHR) targeted therapeutics development and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Melanocyte-Stimulating Hormone Receptor (Melanocortin Receptor 1 or MC1-R or MC1R or MSHR)
- The report reviews Melanocyte-Stimulating Hormone Receptor (Melanocortin Receptor 1 or MC1-R or MC1R or MSHR) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Melanocyte-Stimulating Hormone Receptor (Melanocortin Receptor 1 or MC1-R or MC1R or MSHR) targeted therapeutics and enlists all their major and minor projects
- The report assesses Melanocyte-Stimulating Hormone Receptor (Melanocortin Receptor 1 or MC1-R or MC1R or MSHR) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Melanocyte-Stimulating Hormone Receptor (Melanocortin Receptor 1 or MC1-R or MC1R or MSHR) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Melanocyte-Stimulating Hormone Receptor (Melanocortin Receptor 1 or MC1-R or MC1R or MSHR)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Melanocyte-Stimulating Hormone Receptor (Melanocortin Receptor 1 or MC1-R or MC1R or MSHR) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • Mallinckrodt Plc
  • Retrophin Inc.
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Melanocyte-Stimulating Hormone Receptor (Melanocortin Receptor 1 or MC1-R or MC1R or MSHR) Overview

Therapeutics Development

Melanocyte-Stimulating Hormone Receptor (Melanocortin Receptor 1 or MC1-R or MC1R or MSHR) - Products under Development by Stage of Development

Melanocyte-Stimulating Hormone Receptor (Melanocortin Receptor 1 or MC1-R or MC1R or MSHR) - Products under Development by Therapy Area

Melanocyte-Stimulating Hormone Receptor (Melanocortin Receptor 1 or MC1-R or MC1R or MSHR) - Products under Development by Indication

Melanocyte-Stimulating Hormone Receptor (Melanocortin Receptor 1 or MC1-R or MC1R or MSHR) - Pipeline Products Glance

Late Stage Products

Early Stage Products

Melanocyte-Stimulating Hormone Receptor (Melanocortin Receptor 1 or MC1-R or MC1R or MSHR) - Products under Development by Companies

Melanocyte-Stimulating Hormone Receptor (Melanocortin Receptor 1 or MC1-R or MC1R or MSHR) - Therapeutics Assessment

Assessment by Monotherapy/Combination Products

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Melanocyte-Stimulating Hormone Receptor (Melanocortin Receptor 1 or MC1-R or MC1R or MSHR) - Companies Involved in Therapeutics Development

Clinuvel Pharmaceuticals Limited

Mallinckrodt Plc

Palatin Technologies, Inc.

Retrophin Inc.

Melanocyte-Stimulating Hormone Receptor (Melanocortin Receptor 1 or MC1-R or MC1R or MSHR) - Drug Profiles

afamelanotide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ASP-3291 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

corticotropin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cosyntropin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CUV-9900 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PL-8176 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PL-8177 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SRX-1177 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VLRX-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Melanocyte-Stimulating Hormone Receptor (Melanocortin Receptor 1 or MC1-R or MC1R or MSHR) - Dormant Projects

Melanocyte-Stimulating Hormone Receptor (Melanocortin Receptor 1 or MC1-R or MC1R or MSHR) - Discontinued Products

Melanocyte-Stimulating Hormone Receptor (Melanocortin Receptor 1 or MC1-R or MC1R or MSHR) - Featured News & Press Releases

Mar 24, 2016: NICE’s technical team invited stakeholders with an interest in the treatment of erythropoietic protoporphyria

Feb 16, 2016: Clinuvel brief on European commercialisation

Feb 12, 2016: SCENESSE receives US FDA orphan designation for cutaneous porphyrias

Dec 03, 2015: Positive preliminary results in Singaporean vitiligo study

Dec 03, 2015: Update on North American vitiligo program for SCENESSE

Nov 09, 2015: Mallinckrodt Study Shows Acthar Reduces Disease Activity in Patients with Persistently Active Systemic Lupus Erythematosus

Oct 13, 2015: Clinical Data on Mallinckrodt Pharmaceuticals' H.P. Acthar Gel to be Unveiled at American College of Rheumatology

Oct 08, 2015: Clinical Data on Mallinckrodt Pharmaceuticals' H.P. Acthar Gel to be Unveiled at American College of Rheumatology

Aug 27, 2015: FDA grants Clinuvel a Type C Meeting

Jul 02, 2015: New England Journal of Medicine publishes pivotal Phase III SCENESSE studies

Jul 01, 2015: Treatment Reduces Symptoms in Syndrome that Causes Extreme Light Sensitivity

Jul 01, 2015: Treatment Reduces Symptoms in Syndrome that Causes Extreme Light Sensitivity

Jun 05, 2015: SCENESSE Commercialisation Update

May 05, 2015: Clinuvel announces innovative melanocortin for new indications

Apr 22, 2015: SolaranRx’s SRX-1177 Receives FDA Orphan Drug Designation as Malignant Melanoma Treatment

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Indication, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Number of Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Pipeline by Clinuvel Pharmaceuticals Limited, H1 2016

Pipeline by Mallinckrodt Plc, H1 2016

Pipeline by Palatin Technologies, Inc., H1 2016

Pipeline by Retrophin Inc., H1 2016

Dormant Projects, H1 2016

Discontinued Products, H1 2016

List of Figures

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Top 10 Indication, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Mechanism of Actions, H1 2016

Number of Products by Stage and Mechanism of Actions, H1 2016

Number of Products by Routes of Administration, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Molecule Types, H1 2016

Number of Products by Stage and Molecule Type, H1 2016
Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6

FEATURED COMPANIES

  • Mallinckrodt Plc
  • Retrophin Inc.
  • MORE
According to our recently published report 'Melanocyte-Stimulating Hormone Receptor – Pipeline Review, H1 2016'; Melanocyte-Stimulating Hormone Receptor (Melanocortin Receptor 1 or MC1-R or MC1R or MSHR) pipeline Target constitutes close to 9 molecules. Out of which approximately 9 molecules are developed by Companies.

Furthermore, the report says; Melanocyte-Stimulating Hormone Receptor (Melanocortin Receptor 1 or MC1-R or MC1R or MSHR) Melanocyte-stimulating hormone receptor (MSHR) also known as melanocortin 1 receptor (MC1R), is a G protein–coupled receptor that binds to a peptide hormones known as the melanocortins, which include adrenocorticotropic hormone (ACTH). When activated by alpha-MSH, MC1R initiates a complex signaling cascade that leads to the production of the brown or black pigment eumelanin. The receptor also antagonize by agouti signalling peptide which reverts the cell back to producing the yellow or red phaeomelanin.

The report 'Melanocyte-Stimulating Hormone Receptor – Pipeline Review, H1 2016' outlays comprehensive information on the Melanocyte-Stimulating Hormone Receptor (Melanocortin Receptor 1 or MC1-R or MC1R or MSHR) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Melanocyte-Stimulating Hormone Receptor (Melanocortin Receptor 1 or MC1-R or MC1R or MSHR) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases. Currently, The molecules developed by Companies in Phase III, Phase II and Preclinical stages are 2, 1 and 6 respectively.
Note: Product cover images may vary from those shown
5 of 6
Clinuvel Pharmaceuticals Limited
Mallinckrodt Plc
Palatin Technologies, Inc.
Retrophin Inc.
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll